26 results on '"Deroose, C. M."'
Search Results
2. Prognostic superiority of International Prognostic Index over [18F]FDG PET/CT volumetric parameters in post-transplant lymphoproliferative disorder
- Author
-
Montes de Jesus, F., Dierickx, D., Vergote, V., Noordzij, W., Dierckx, R. A. J. O., Deroose, C. M., Glaudemans, A. W. J. M., Gheysens, O., and Kwee, T. C.
- Published
- 2021
- Full Text
- View/download PDF
3. Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases After Initial Peptide Receptor Radionuclide Therapy
- Author
-
Braat, A. J. A. T., Ahmadzadehfar, H., Kappadath, S. C., Stothers, C. L., Frilling, A., Deroose, C. M., Flamen, P., Brown, D. B., Sze, D. Y., Mahvash, A., and Lam, M. G. E. H.
- Published
- 2020
- Full Text
- View/download PDF
4. Fulminant ectopic Cushing's syndrome caused by metastatic small intestine neuroendocrine tumour -- a case report and review of the literature.
- Author
-
Alliet, B., Severi, C., Veekmans, T., Cuypers, J., Topal, H., Deroose, C. M., Roskams, T., Bex, M., and Dekervel, J.
- Published
- 2024
- Full Text
- View/download PDF
5. Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases: International Multicenter Study on Efficacy and Toxicity
- Author
-
Braat, A. J. A. T., Kappadath, S. C., Ahmadzadehfar, H., Stothers, C. L., Frilling, A., Deroose, C. M., Flamen, P., Brown, D. B., Sze, D. Y., Mahvash, A., and Lam, M. G. E. H.
- Published
- 2019
- Full Text
- View/download PDF
6. Using PET for therapy monitoring in oncological clinical trials: challenges ahead
- Author
-
Deroose, C. M., Stroobants, S., Liu, Y., Shankar, L. K., and Bourguet, P.
- Published
- 2017
- Full Text
- View/download PDF
7. Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours
- Author
-
Van Binnebeek, S., Vanbilloen, B., Baete, K., Terwinghe, C., Koole, M., Mottaghy, F. M., Clement, P. M., Mortelmans, L., Bogaerts, K., Haustermans, K., Nackaerts, K., Van Cutsem, E., Verslype, C., Verbruggen, A., and Deroose, C. M.
- Published
- 2016
- Full Text
- View/download PDF
8. P1151: METABOLIC TUMOR VOLUME IMPROVES OUTCOME PREDICTION IN UNTREATED MANTLE CELL LYMPHOMA
- Author
-
Vergote, V. K., primary, Verhoef, G., additional, Janssens, A., additional, Woei-a-jin, F. S., additional, Laenen, A., additional, Tousseyn, T., additional, Dierickx, D., additional, and Deroose, C. M., additional
- Published
- 2022
- Full Text
- View/download PDF
9. ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors
- Author
-
Borbath, I., Pape, U. -F., Deprez, P. H., Bartsch, D. K., Caplin, M., Falconi, M., Garcia-Carbonero, R., Grozinsky-Glasberg, S., Jensen, R. T., Arnold, R., Ruszniewski, P., Toumpanakis, C., Valle, J. W., O'Toole, D., Belli, S. H., Castano, J. P., Chen, J., Costa, F. P., Couvelard, A., de Herder, W. W., Deroose, C. M., Dromain, C., Faggiano, A., Falkerby, J., Fazio, N., Frilling, A., Grande, E., Hand, P., Hicks, R. J., Horsch, D., Howe, J. R., Kloppel, G., Kolarova, T., Kos-Kudla, B., Koumarianou, A., Krejs, G. J., Krenning, E. P., Krishna, B. A., Leyden, S., Masui, T., Niederle, B., Nieveen van Dijkum, E. J., Oberg, K., Pavel, M., Perren, A., Prasad, V., Ramage, J. K., Reed, N. S., Rindi, G., Gemelli, A., Rinke, A., Rothmund, M., Singh, S., Sundin, A., Velthuysen, M. F. V., Verslype, C., Vullierme, M. P., Welin, S., Wiedenmann, B., Zhao, H., Graduate School, Surgery, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service de gastro-entérologie, and UCL - (SLuc) Unité d'oncologie médicale
- Subjects
Cellular and Molecular Neuroscience ,Neuroendocrine Tumors ,Endocrinology ,neuroendocrine neoplasms ,Endocrine and Autonomic Systems ,Endocrinology, Diabetes and Metabolism ,Humans ,Endoscopy ,endoscopy ,standardised reporting - Abstract
Despite efforts from various endoscopy societies, reporting in the field of endoscopy remains extremely heterogeneous. Harmonisation of clinical practice in endoscopy has been highlighted by application of many clinical practice guidelines and standards pertaining to the endoscopic procedures and reporting are underlined. The aim of the proposed "standardised reporting" is to (1) facilitate recognition of gastrointestinal neuroendocrine neoplasms (NEN) on initial endoscopy, (2) to enable interdisciplinary decision making for treatment by a multidisciplinary team, (3) to provide a basis for a standardised endoscopic follow-up which allows detection of recurrence or progression reliably, (4) to make endoscopic reports on NEN comparable between different units, and (5) to allow research collaboration between NEN centres in terms of consistency of their endoscopic data. The ultimate goal is to improve disease management, patient outcome and reduce the diagnostic burden on the side of the patient by ensuring the highest possible diagnostic accuracy and validity of endoscopic exams and possibly interventions.
- Published
- 2022
10. AI18F-3p-C-NETA-TATE: Combining a versatile and highly effective chelator with an established somatostatin analogue
- Author
-
Ahenkorah, S., Murce, E., Seimbille, Y., Cardinaels, T., Deroose, C. M., Bormans, G., Ooms, M., Cleeren, F., and Radiology & Nuclear Medicine
- Subjects
SDG 3 - Good Health and Well-being - Abstract
Aim/Introduction: Somatostatin-based radiopharmaceuticals (e.g. [68Ga]Ga-DOTATATE and [177Lu]Lu-DOTATATE) have been used to diagnose, monitor, and treat neuroendocrine tumour patients with great success. [18F]AlF-NOTA-octreotide, a promising 18F-labeled somatostatin analogue and potential alternative for 68GaDOTA-peptides, is under clinical evaluation. Ideally, the same precursor (combination of chelator-linker-vector) can be used for production of both diagnostic and therapeutic radiopharmaceuticals with very similar (e.g. Al18F/213Bi/177Lu) or identical (e.g. complementary Tb-radionuclides) pharmacokinetic properties, allowing accurate, personalised dosimetry estimation and radionuclide therapy of NET patients. In this study we evaluate the versatile and highly effective chelator 3p-C-NETA3 and present first results of radiosynthesis and stability of Al[18F]F-3p-C-NETA-TATE. Materials and Methods: 3p-C-NETA was radiolabelled with diagnostic (68Ga, Al18F) or therapeutic (177Lu,161Tb,213Bi) radionuclides at different temperatures. The in vitro stability of the corresponding radiocomplexes was determined in PBS and human serum at 37 °C. 3p-C-NETA-TATE was synthesised using standard solid-phase peptide synthesis and purifed using HPLC. Al[18F]F-3p-C-NETA-TATE was synthesised in an automated AllInOne module and analysed using radio-HPLC. Finally, the in vitro stability of Al[18F]F-3p-C-NETA-TATE was evaluated in formulation buffer, PBS and human serum at 37 °C. Results: 3p-C-NETA was efficiently labelled with 177Luand 213Bi (RCY>95%) at room temperature and with 161Tb(>95%) and 68Ga (>90%) at 55 °C. Al18F-labeling required a higher temperature of 95 °C to achieve good yields (>85%).The 177Lu- and 161Tb-3p-C-NETA-complex showed excellent invitro stability in both PBS and human serum over a period of eight days (97% intact). We also observed high in vitro stability up to 2 h for Al[18F]F-3p-C-NETA-TATE (>93% intact in PBS and human serum). In contrast, [68Ga]Ga-3p-C-NETA was stable in PBS (>90% intact), but not in human serum (only 60% intact after 2h). Al[18F]F-3p-C-NETA-TATE was obtained in good RCY (56%) and radiochemical purity (98%). Al[18F]F-3pC-NETA-TATE displayed excellent in vitro stability with >95%intact tracer after 4 hours in all tested conditions. Conclusion: 3p-C-NETA is an excellent chelator that can be used for both targeted radionuclide therapy (177Lu, 213Bi and 161Tb) and diagnostic applications (Al18F) and has the potential to replace DOTA analogues in current clinical use. Al[18F]F-3p-CNETA-TATE will be further evaluated using µPET/MRI imaging in healthy rats and SSTR2 positive tumour mice, in a head-to-head comparison with Al18F-NOTA-octreotide. °
- Published
- 2021
11. Semi-Quantitative Characterization of Post-Transplant Lymphoproliferative Disorder Morphological Subtypes with [F]FDG PET/CT
- Author
-
Montes de Jesus, Felipe, Vergote, V, Noordzij, W, Dierickx, D, Dierckx, R A J O, Diepstra, A, Tousseyn, T, Gheysens, O, Kwee, T C, Deroose, C M, Glaudemans, A W J M, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service de médecine nucléaire, and UCL - (SLuc) Centre du cancer
- Subjects
surgical procedures, operative ,2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography ,hemic and lymphatic diseases ,standardized uptake value ,semi-quantification ,post-transplant lymphoproliferative disorder ,FDG-PET/CT - Abstract
Post-transplant lymphoproliferative disorder (PTLD) is a complication of organ transplantation classified according to the WHO as nondestructive, polymorphic, monomorphic, and classic Hodgkin Lymphoma subtypes. In this retrospective study, we investigated the potential of semi-quantitative 2-[F]fluoro-2-deoxy-D-glucose ([F]FDG) PET/computed tomography (CT)-based parameters to differentiate between the PTLD morphological subtypes. 96 patients with histopathologically confirmed PTLD and baseline [F]FDG PET/CT between 2009 and 2019 were included. Extracted semi-quantitative measurements included: Maximum, peak, and mean standardized uptake value (SUV, SUV, and SUV). Median SUVs were highest for monomorphic PTLD followed by polymorphic and nondestructive subtypes. The median SUV at the biopsy site was significantly higher in monomorphic PTLD (17.8, interquartile range (IQR):16) than in polymorphic subtypes (9.8, IQR:13.4) and nondestructive (4.1, IQR:6.1) ( = 0.04 and ≤ 0.01, respectively). An SUV ≥ 24.8 was always indicative of a monomorphic PTLD in our dataset. Nevertheless, there was a considerable overlap in SUV across the different morphologies. The median SUV at the biopsy site was significantly higher in monomorphic PTLD than polymorphic and nondestructive subtypes. However, due to significant SUV overlap across the different subtypes, these values may only serve as an indication of PTLD morphology, and SUV-based parameters cannot replace histopathological classification.
- Published
- 2021
12. Current practice in approaching controversial diagnostic and therapeutic topics in gastroenteropancreatic neuroendocrine neoplasm management. Belgian multidisciplinary expert discussion based on a modified Delphi method
- Author
-
Cuyle, P. -J, Geboes, K., Carton, S., Casneuf, V., Decaestecker, J., Man, M., Demolin, G., Deroose, C. M., Vleeschouwer, C., Flamen, P., Hendlisz, A., Hoorens, A., Janssens, J., Karfis, I., Lybaert, W., Machiels, G., Monsaert, E., Sinapi, I., Cutsem, E., Vandamme, T., Ivan Borbath, Verslype, C., UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service de gastro-entérologie, and UCL - (SLuc) Unité d'oncologie médicale
- Subjects
Neuroendocrine Tumors ,Belgium ,Intestinal Neoplasms ,neuroendocrine carcinoma ,Humans ,Human medicine ,Somatostatin ,multidisciplinary team (MDT) ,Carcinoma, Neuroendocrine ,neuro-endocrine tumor - Abstract
Background and study aims: Neuroendocrine neoplasms (NENs) are relatively rare, with marked clinical and biological heterogeneity. Consequently, many controversial areas remain in diagnosis and optimal treatment stratification for NEN patients. We wanted to describe current clinical practice regarding controversial NEN topics and stimulate critical thinking and mutual learning among a Belgian multidisciplinary expert panel Patients and methods: A 3-round, Delphi method based project, coordinated by a steering committee (SC), was applied to a predefined multidisciplinary NEN expert panel studying the following controversial topics : factors guiding therapeutic decision making, the use of somatostatin analogues (SSA) in adjuvant setting, the interference between non-radioactive and radioactive SSAs, challenging small intestine neuroendocrine tumor (NET) cases, the approach of the carcinoid syndrome, the role of chemotherapy in well differentiated NET, the relevance of NET G3 and neuroendocrine carcinoma subclassification and the role of imaging techniques in NEN management. Results: A high level of consensus exists regarding the necessary diagnostic work-up, use of imaging techniques and interference between non-radioactive and radioactive SSAs. However, the prognostic impact of tumor functionality might be overrated and adequate diarrhea differential diagnostic work-up in these patients is underused. Significant differences are seen between individual experts and centers regarding treatment preferences both on the treatment modality level, as well as the choice of specific drugs (e.g. chemotherapy regimen). Conclusions: A Delphi-like multi-round expert discussion proves useful to boost critical thinking and discussion among experts of different background, as well as to describe current clinical practice and stimulate mutual learning in the absence of high-level scientific guidance.
- Published
- 2020
13. Metabolic-structural concordance in paraneoplastic limbic encephalitis
- Author
-
Goffin, K. E., Ooms, D., Ahmad, R., Demaerel, P., Van Paesschen, W., Van Laere, K., Vansteenkiste, J., Deroose, C. M., and Gheysens, O.
- Published
- 2016
- Full Text
- View/download PDF
14. Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases After Initial Peptide Receptor Radionuclide Therapy
- Author
-
Braat, A. J. A. T., primary, Ahmadzadehfar, H., additional, Kappadath, S. C., additional, Stothers, C. L., additional, Frilling, A., additional, Deroose, C. M., additional, Flamen, P., additional, Brown, D. B., additional, Sze, D. Y., additional, Mahvash, A., additional, and Lam, M. G. E. H., additional
- Published
- 2019
- Full Text
- View/download PDF
15. Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases After Initial Peptide Receptor Radionuclide Therapy.
- Author
-
Braat, A. J. A. T., Ahmadzadehfar, H., Kappadath, S. C., Stothers, C. L., Frilling, A., Deroose, C. M., Flamen, P., Brown, D. B., Sze, D. Y., Mahvash, A., and Lam, M. G. E. H.
- Subjects
PEPTIDE receptors ,RADIOEMBOLIZATION ,LIVER metastasis ,RADIOISOTOPES ,MICROSPHERES ,RADIOISOTOPE therapy ,LATEX ,LIVER tumors ,CELL receptors ,RETROSPECTIVE studies ,TREATMENT effectiveness ,NEUROENDOCRINE tumors ,RADIOISOTOPE brachytherapy - Abstract
Purpose: Peptide receptor radionuclide therapy (PRRT) and radioembolization are increasingly used in neuroendocrine neoplasms patients. However, concerns have been raised on cumulative hepatotoxicity. The aim of this sub-analysis was to investigate hepatotoxicity of yttrium-90 resin microspheres radioembolization in patients who were previously treated with PRRT.Methods: Patients treated with radioembolization after systemic radionuclide treatment were retrospectively analysed. Imaging response according to response evaluation criteria in solid tumours (RECIST) v1.1 and clinical response after 3 months were collected. Clinical, biochemical and haematological toxicities according to common terminology criteria for adverse events (CTCAE) v4.03 were also collected. Specifics on prior PRRT, subsequent radioembolization treatments, treatments after radioembolization and overall survival (OS) were collected.Results: Forty-four patients were included, who underwent a total of 58 radioembolization procedures, of which 55% whole liver treatments, at a median of 353 days after prior PRRT. According to RECIST 1.1, an objective response rate of 16% and disease control rate of 91% were found after 3 months. Clinical response was seen in 65% (15/23) of symptomatic patients after 3 months. Within 3 months, clinical toxicities occurred in 26%. Biochemical and haematological toxicities CTCAE grade 3-4 occurred in ≤ 10%, apart from lymphocytopenia (42%). Radioembolization-related complications occurred in 5% and fatal radioembolization-induced liver disease in 2% (one patient). A median OS of 3.5 years [95% confidence interval 1.8-5.1 years] after radioembolization for the entire study population was found.Conclusion: Radioembolization after systemic radionuclide treatments is safe, and the occurrence of radioembolization-induced liver disease is rare.Level Of Evidence: 4, case series. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
16. Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases: International Multicenter Study on Efficacy and Toxicity.
- Author
-
Braat, A. J. A. T., Kappadath, S. C., Ahmadzadehfar, H., Stothers, C. L., Frilling, A., Deroose, C. M., Flamen, P., Brown, D. B., Sze, D. Y., Mahvash, A., and Lam, M. G. E. H.
- Abstract
Purpose: Radioembolization of liver metastases of neuroendocrine neoplasms (NEN) has shown promising results; however, the current literature is of limited quality. A large international, multicentre retrospective study was designed to address several shortcomings of the current literature.Materials: 244 NEN patients with different NEN grades were included.Methods: Primary outcome parameters were radiologic response 3 and 6 months after treatment according to RECIST 1.1 and mRECIST. Secondary outcome parameters included clinical response, clinical and biochemical toxicities.Results: Radioembolization resulted in CR in 2%, PR in 14%, SD in 75% and PD 9% according to RECIST 1.1 and in CR in 8%, PR in 35%, SD in 48% and PD in 9% according to mRECIST. Objective response rates improved over time in 20% and 26% according to RECIST 1.1. and mRECIST, respectively. Most common new grade 3-4 biochemical toxicity was lymphocytopenia (6.7%). No unexpected clinical toxicities occurred. Radioembolization-specific complications occurred in < 4%. In symptomatic patients, improvement and resolution of symptoms occurred in 44% and 34%, respectively. Median overall survival from first radioembolization was 3.7, 2.7 and 0.7 years for G1, G2 and G3, respectively. Objective response is independent of NEN grade or primary tumour origin. Significant prognostic factors for survival were NEN grade/Ki67 index, ≥ 75% intrahepatic tumour load, the presence of extrahepatic disease and disease control rate according to RECIST 1.1.Conclusion: Safety and efficacy of radioembolization in NEN patients was confirmed with a high disease control rate of 91% in progressive patients and alleviation of NEN-related symptoms in 79% of symptomatic patients.Level of evidence: 4. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours
- Author
-
Van Binnebeek, S., primary, Vanbilloen, B., additional, Baete, K., additional, Terwinghe, C., additional, Koole, M., additional, Mottaghy, F. M., additional, Clement, P. M., additional, Mortelmans, L., additional, Bogaerts, K., additional, Haustermans, K., additional, Nackaerts, K., additional, Van Cutsem, E., additional, Verslype, C., additional, Verbruggen, A., additional, and Deroose, C. M., additional
- Published
- 2015
- Full Text
- View/download PDF
18. Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours.
- Author
-
Binnebeek, S., Vanbilloen, B., Baete, K., Terwinghe, C., Koole, M., Mottaghy, F., Clement, P., Mortelmans, L., Bogaerts, K., Haustermans, K., Nackaerts, K., Van Cutsem, E., Verslype, C., Verbruggen, A., Deroose, C., Van Binnebeek, S, Mottaghy, F M, Clement, P M, and Deroose, C M
- Subjects
SINGLE-photon emission computed tomography ,POSITRON emission tomography ,NEUROENDOCRINE tumors ,TUMORS ,CARCINOID ,BONE tumor diagnosis ,BONE tumors ,CLINICAL trials ,COMPARATIVE studies ,COMPUTED tomography ,GALLIUM isotopes ,LIVER tumors ,RESEARCH methodology ,MEDICAL cooperation ,OCTREOTIDE acetate ,RADIOISOTOPES ,RADIOPHARMACEUTICALS ,RESEARCH ,SOMATOSTATIN ,EVALUATION research ,DIAGNOSIS - Abstract
Objectives: To compare the diagnostic accuracy of (111)In-pentetreotide-scintigraphy with (68)Ga-DOTATOC-positron emission tomography (PET)/computed tomography (CT) in patients with metastatic-neuroendocrine tumour (NET) scheduled for peptide receptor radionuclide therapy (PRRT). Incremental lesions (ILs) were defined as lesions observed on only one modality.Methods: Fifty-three metastatic-NET-patients underwent (111)In-pentetreotide-scintigraphy (24 h post-injection; planar+single-photon emission CT (SPECT) abdomen) and whole-body (68)Ga-DOTATOC-PET/CT. SPECT and PET were compared in a lesion-by-lesion and organ-by-organ analysis, determining the total lesions and ILs for both modalities.Results: Significantly more lesions were detected on (68)Ga-DOTATOC-PET/CT versus (111)In-pentetreotide-scintigraphy. More specifically, we observed 1,098 lesions on PET/CT (range: 1-105; median: 15) versus 660 on SPECT (range: 0-73, median: 9) (p<0.0001), with 439 PET-ILs (42/53 patients) and one SPECT-IL (1/53 patients). The sensitivity for PET/CT was 99.9 % (95 % CI, 99.3-100.0), for SPECT 60.0 % (95 % CI, 48.5-70.2). The organ-by-organ analysis showed that the PET-ILs were most frequently visualized in liver and skeleton.Conclusion: Ga-DOTATOC-PET/CT is superior for the detection of NET-metastases compared to (111)In-pentetreotide SPECT.Key Points: Somatostatin receptor PET is superior to SPECT in detecting NET metastases. PET is the scintigraphic method for accurate depiction of NET tumour burden. The sensitivity of PET is twofold higher than the sensitivity of SPECT. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
19. Evaluation of Three MRI-Based Anatomical Priors for Quantitative PET Brain Imaging
- Author
-
Vunckx, K., primary, Atre, A., additional, Baete, K., additional, Reilhac, A., additional, Deroose, C. M., additional, Van Laere, K., additional, and Nuyts, J., additional
- Published
- 2012
- Full Text
- View/download PDF
20. A textural feature based tumor therapy response prediction model for longitudinal evaluation with PET imaging.
- Author
-
George, J., Claes, P., Vunckx, K., Tejpar, S., Deroose, C. M., Nuyts, J., Loeckx, D., and Suetens, P.
- Abstract
Early therapy response prediction, employing biomarkers such as 18F-fluorodeoxyglucose (FDG) followed with positron emission tomography (PET), is an actively researched topic. Traditionally, only the first order intensity based feature estimates are used for the response evaluations. In this work, we focus on the predictive power of lesion texture along with traditional features in follow up studies. Both standard and textural features are extracted after delineating the lesions with state-of-the-art methods. We propose subspace learning to reduce the influence of delineation parameters and to represent each patient as a Grassmann manifold spanned by the extracted feature subspace. We also propose parallel analysis (PA) to find out the optimal subspace dimensionality. Weighted projection distance between longitudinal subspaces is checked for concordance with the progression outcome using time dependent receiver operating characteristics (ROC). The preliminary clinical results suggest that higher order lesion textures have an added value in response evaluations. [ABSTRACT FROM PUBLISHER]
- Published
- 2012
- Full Text
- View/download PDF
21. Does 11C-choline PET-CT contribute to multiparametric MRI for prostate cancer localisation?
- Author
-
Van den Bergh, L, Isebaert, S, Koole, M, Oyen, R, Joniau, S, Lerut, E, Deroose, C M, De Keyzer, F, Van Poppel, H, and Haustermans, K
- Abstract
Background and Purpose: The aim of this work was to determine whether 11C-choline positron emission tomography (PET)-computed tomography (CT) makes a positive contribution to multiparametric magnetic resonance imaging (MRI) for localisation of intraprostatic tumour nodules.Patients and Methods: A total of 73 patients with biopsy-proven intermediate- and high-risk prostate cancer were enrolled in a prospective imaging study consisting of T2-weighted (T2w), dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) MRI and 11C-choline PET-CT before radical prostatectomy. Cancerous regions were delineated on the whole-mount prostatectomy sections and on the different MRI modalities and analysed in 24 segments per patient (3 sections, 8 segments each). To analyse PET-CT images, standardized uptake values (SUV) were calculated per segment.Results: In total, 1,752 segments were analyzed of which 708 (40.4%) were found to be malignant. A high specificity (94.7, 93.6 and 92.2%) but relatively low sensitivity (31.2, 24.9 and 44.1%) for tumour localisation was obtained with T2w, DCE and DW MRI, respectively. Sensitivity values significantly increased when combining all MRI modalities (57.2%). For PET-CT, mean SUVmax of malignant octants was significantly higher than mean SUVmax of benign octants (3.68±1.30 vs. 3.12±1.02, p<0.0001). In terms of accuracy, the benefit of adding PET-CT to (multiparametric) MRI was less than 1%.Conclusion: The additional value of 11C-choline PET-CT to MRI in localising intraprostatic tumour nodules is limited, especially when multiparametric MRI is used. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
22. Fat Induces Glucose Metabolism in Nontransformed Liver Cells and Promotes Liver Tumorigenesis
- Author
-
Rebeca Alba Rubio, Shinya Kuroda, Chantal Mathieu, Yasuaki Karasawa, Jos van Pelt, Jia Zeng, Roberta Schmieder, Thomas G. P. Grunewald, Johannes V. Swinnen, Bryan Holvoet, Jonas Dehairs, Masashi Fujii, Roman Vangoitsenhoven, Francesco Napolitano, Diego di Bernardo, James Dooley, Koen Veys, Adrian Liston, Dorien Broekaert, Lindsay A. Broadfield, Juan Fernández-García, Sarah-Maria Fendt, Kim Vriens, Miki Eto, Diether Lambrechts, Joao A.G. Duarte, Katrien De Bock, Suguru Fujita, Christophe Deroose, Mélanie Planque, Joke Van Elsen, Broadfield, L. A., Duarte, J. A. G., Schmieder, R., Broekaert, D., Veys, K., Planque, M., Vriens, K., Karasawa, Y., Napolitano, F., Fujita, S., Fujii, M., Eto, M., Holvoet, B., Vangoitsenhoven, R., Fernandez-Garcia, J., Van Elsen, J., Dehairs, J., Zeng, J., Dooley, J., Rubio, R. A., Van Pelt, J., Grunewald, T. G. P., Liston, A., Mathieu, C., Deroose, C. M., Swinnen, J. V., Lambrechts, D., Di Bernardo, D., Kuroda, S., De Bock, K., and Fendt, S. -M.
- Subjects
0301 basic medicine ,Proteomics ,Cancer Research ,Glucose uptake ,Palmitates ,Palmitate ,Mice ,Random Allocation ,0302 clinical medicine ,Serine ,Hepatocyte ,Dietary Fat ,chemistry.chemical_classification ,Chemistry ,Fatty Acids ,Liver Neoplasms ,3. Good health ,Cell Transformation, Neoplastic ,Oncology ,Liver Neoplasm ,030220 oncology & carcinogenesis ,Pyruvate carboxylase activity ,Liver cancer ,Reactive Oxygen Specie ,Human ,Transcriptional Activation ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Citric Acid Cycle ,Carbohydrate metabolism ,Peroxisome ,Diet, High-Fat ,Article ,03 medical and health sciences ,Internal medicine ,Diabetes mellitus ,medicine ,Peroxisomes ,Animals ,Humans ,Lactic Acid ,Obesity ,Carcinogen ,Pyruvate Carboxylase ,Reactive oxygen species ,Animal ,Proteomic ,Lipid metabolism ,Glucose Tolerance Test ,medicine.disease ,Lipid Metabolism ,Dietary Fats ,Mice, Inbred C57BL ,030104 developmental biology ,Endocrinology ,Glucose ,Hepatocytes ,Reactive Oxygen Species ,Fatty Acid - Abstract
Hepatic fat accumulation is associated with diabetes and hepatocellular carcinoma (HCC). Here, we characterize the metabolic response that high-fat availability elicits in livers before disease development. After a short term on a high-fat diet (HFD), otherwise healthy mice showed elevated hepatic glucose uptake and increased glucose contribution to serine and pyruvate carboxylase activity compared with control diet (CD) mice. This glucose phenotype occurred independently from transcriptional or proteomic programming, which identifies increased peroxisomal and lipid metabolism pathways. HFD-fed mice exhibited increased lactate production when challenged with glucose. Consistently, administration of an oral glucose bolus to healthy individuals revealed a correlation between waist circumference and lactate secretion in a human cohort. In vitro, palmitate exposure stimulated production of reactive oxygen species and subsequent glucose uptake and lactate secretion in hepatocytes and liver cancer cells. Furthermore, HFD enhanced the formation of HCC compared with CD in mice exposed to a hepatic carcinogen. Regardless of the dietary background, all murine tumors showed similar alterations in glucose metabolism to those identified in fat exposed nontransformed mouse livers, however, particular lipid species were elevated in HFD tumor and nontumor-bearing HFD liver tissue. These findings suggest that fat can induce glucose-mediated metabolic changes in nontransformed liver cells similar to those found in HCC. Significance: With obesity-induced hepatocellular carcinoma on a rising trend, this study shows in normal, nontransformed livers that fat induces glucose metabolism similar to an oncogenic transformation.
- Published
- 2021
23. Semi-Quantitative Characterization of Post-Transplant Lymphoproliferative Disorder Morphological Subtypes with [ 18 F]FDG PET/CT.
- Author
-
Montes de Jesus F, Vergote V, Noordzij W, Dierickx D, Dierckx RAJO, Diepstra A, Tousseyn T, Gheysens O, Kwee TC, Deroose CM, and Glaudemans AWJM
- Abstract
Background: Post-transplant lymphoproliferative disorder (PTLD) is a complication of organ transplantation classified according to the WHO as nondestructive, polymorphic, monomorphic, and classic Hodgkin Lymphoma subtypes. In this retrospective study, we investigated the potential of semi-quantitative 2-[
18 F]fluoro-2-deoxy-D-glucose ([18 F]FDG) PET/computed tomography (CT)-based parameters to differentiate between the PTLD morphological subtypes. Methods: 96 patients with histopathologically confirmed PTLD and baseline [18 F]FDG PET/CT between 2009 and 2019 were included. Extracted semi-quantitative measurements included: Maximum, peak, and mean standardized uptake value (SUVmax , SUVpeak , and SUVmean ). Results: Median SUVs were highest for monomorphic PTLD followed by polymorphic and nondestructive subtypes. The median SUVpeak at the biopsy site was significantly higher in monomorphic PTLD (17.8, interquartile range (IQR):16) than in polymorphic subtypes (9.8, IQR:13.4) and nondestructive (4.1, IQR:6.1) ( p = 0.04 and p ≤ 0.01, respectively). An SUVpeak ≥ 24.8 was always indicative of a monomorphic PTLD in our dataset. Nevertheless, there was a considerable overlap in SUV across the different morphologies. Conclusion: The median SUVpeak at the biopsy site was significantly higher in monomorphic PTLD than polymorphic and nondestructive subtypes. However, due to significant SUV overlap across the different subtypes, these values may only serve as an indication of PTLD morphology, and SUV-based parameters cannot replace histopathological classification.- Published
- 2021
- Full Text
- View/download PDF
24. Current practice in approaching controversial diagnostic and therapeutic topics in gastroenteropancreatic neuroendocrine neoplasm management. Belgian multidisciplinary expert discussion based on a modified Delphi method.
- Author
-
Cuyle PJ, Geboes K, Carton S, Casneuf V, Decaestecker J, De Man M, Demolin G, Deroose CM, De Vleeschouwer C, Flamen P, Hendlisz A, Hoorens A, Janssens J, Karfis I, Lybaert W, Machiels G, Monsaert E, Sinapi I, Van Cutsem E, Vandamme T, Borbath I, and Verslype C
- Subjects
- Belgium, Humans, Somatostatin, Carcinoma, Neuroendocrine, Intestinal Neoplasms, Neuroendocrine Tumors diagnosis, Neuroendocrine Tumors therapy
- Abstract
Background and Study Aims: Neuroendocrine neoplasms (NENs) are relatively rare, with marked clinical and biological heterogeneity. Consequently, many controversial areas remain in diagnosis and optimal treatment stratification for NEN patients. We wanted to describe current clinical practice regarding controversial NEN topics and stimulate critical thinking and mutual learning among a Belgian multidisciplinary expert panel., Patients and Methods: A 3-round, Delphi method based project, coordinated by a steering committee (SC), was applied to a predefined multidisciplinary NEN expert panel studying the following controversial topics : factors guiding therapeutic decision making, the use of somatostatin analogues (SSA) in adjuvant setting, the interference between non-radioactive and radioactive SSAs, challenging small intestine neuroendocrine tumor (NET) cases, the approach of the carcinoid syndrome, the role of chemotherapy in well differentiated NET, the relevance of NET G3 and neuroendocrine carcinoma subclassification and the role of imaging techniques in NEN management., Results: A high level of consensus exists regarding the necessary diagnostic work-up, use of imaging techniques and interference between non-radioactive and radioactive SSAs. However, the prognostic impact of tumor functionality might be overrated and adequate diarrhea differential diagnostic work-up in these patients is underused. Significant differences are seen between individual experts and centers regarding treatment preferences both on the treatment modality level, as well as the choice of specific drugs (e.g. chemotherapy regimen)., Conclusions: A Delphi-like multi-round expert discussion proves useful to boost critical thinking and discussion among experts of different background, as well as to describe current clinical practice and stimulate mutual learning in the absence of high-level scientific guidance., (© Acta Gastro-Enterologica Belgica.)
- Published
- 2020
25. Disseminated histoplasmosis in a kidney liver transplant patient from a non-endemic area: A diagnostic challenge.
- Author
-
Carmans L, Van Craenenbroeck A, Lagrou K, Deroose CM, Sagaert X, Wolthuis A, Van Wijngaerden E, and Kuypers DR
- Abstract
Disseminated histoplasmosis is a rare opportunistic infection in non-endemic areas, where the disease is often diagnosed late. The spectrum of clinical manifestations is broad and life-threatening complications occur. We present a detailed case of a kidney liver transplant patient with disseminated histoplasmosis in a non-endemic area. Our case highlights the wide range of pathogens to consider in the immunocompromised patient, the delayed diagnosis of Histoplasmosis Capsulatum in non-endemic areas and the possibility of severe gastrointestinal disease. We also briefly review diagnostic tests and treatment options., Competing Interests: The authors report no declarations of interest., (© 2020 The Authors.)
- Published
- 2020
- Full Text
- View/download PDF
26. PET/CT in the staging of patients with a pelvic mass suspicious for ovarian cancer.
- Author
-
Dauwen H, Van Calster B, Deroose CM, Op de Beeck K, Amant F, Neven P, Berteloot P, Leunen K, Timmerman D, and Vergote I
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Lymph Nodes diagnostic imaging, Lymph Nodes pathology, Lymphatic Metastasis, Middle Aged, Multimodal Imaging methods, Neoplasm Metastasis, Neoplasm Staging, Ovarian Neoplasms pathology, Ovarian Neoplasms surgery, Positron-Emission Tomography, Prospective Studies, Tomography, X-Ray Computed, Ultrasonography, Young Adult, Fluorodeoxyglucose F18, Ovarian Neoplasms diagnostic imaging, Radiopharmaceuticals
- Abstract
Objective: To prospectively assess the value of PET/CT for staging, diagnosis and operability of ovarian cancer, with special attention to the peritoneal spread., Methods: From June 2009 to March 2011, 69 patients with suspicion of having an ovarian cancer underwent an (18)F-FDG PET/CT. To identify the diagnostic value of PET/CT, the results were compared with the findings at diagnostic laparoscopy and/or debulking surgery., Results: There were 56 patients with malignant tumors and 13 with benign tumors. We observed a sensitivity and specificity of 93% and 77%, respectively for malignant tumors with PET/CT. CT alone had a sensitivity and specificity of 96% and 38%, respectively. The overall FIGO classification evaluation for PET/CT and CT were the same. For the evaluation of metastases, the sensitivity of PET/CT was worse, while the specificity was better than CT. Retroperitoneal lymph node metastases were diagnosed better with PET/CT, while there was no difference for peritoneal spread and for the intestines. PET/CT detected another unknown primary tumor in 3 (4.3%) cases., Conclusion: PET/CT is better than CT in detecting retroperitoneal lymph node metastases, but not for peritoneal metastases., (© 2013.)
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.